Cresco Labs (CRLBF) Liabilities from Discontinued Operations (2023 - 2025)
Cresco Labs' (CRLBF) quarterly Liabilities from Discontinued Operations came in at 4975000.0 in Q3 2025, down 6.19% on a QoQ basis from 5303000.0 in Q2 2025.
Cresco Labs (CRLBF) Liabilities from Discontinued Operations (2023 - 2025) Analysis & Trends
Cresco Labs (CRLBF) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 4975000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Cresco Labs | 295.09 Mn | 230.98 Mn | 86.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 4.98 Mn |
| Sep 30, 2025 | 4.98 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Jun 30, 2025 | 5.30 Mn |
| Sep 30, 2023 | 1.30 Mn |
| Sep 30, 2023 | 1.30 Mn |